Cancer Communications

Papers
(The H4-Index of Cancer Communications is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Issue Information465
Issue Information425
279
259
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity252
Issue Information219
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort197
180
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation178
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma162
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma161
Age‐specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross‐sectional study156
Current status and perspectives of esophageal cancer: a comprehensive review144
Kindlin‐1 drives early steps of breast cancer metastasis143
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study139
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy137
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update133
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives113
Issue Information112
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica111
P300/CBP‐associated factor (PCAF)‐mediated acetylation of Fascin at lysine 471 inhibits its actin‐bundling activity and tumor metastasis in esophageal cancer106
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer106
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer104
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence102
N6‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastasis101
101
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h98
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward93
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program93
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases88
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study83
Research trends of cancer metabolism: analysis from a Chinese perspective80
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions80
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial74
73
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity69
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses68
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy65
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates61
Issue Information59
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer59
Cover Image, Volume 45, Issue 651
A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX251
51
Ubiquitination in cancer: mechanisms and therapeutic opportunities48
47
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials47
0.038928031921387